Edition:
India

Diffusion Pharmaceuticals Inc (DFFN.OQ)

DFFN.OQ on NASDAQ Stock Exchange Capital Market

0.53USD
25 Apr 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.53
Open
$0.55
Day's High
$0.55
Day's Low
$0.53
Volume
8,522
Avg. Vol
152,817
52-wk High
$3.93
52-wk Low
$0.50

Chart for

About

Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC)... (more)

Overall

Beta: -0.71
Market Cap(Mil.): $25.24
Shares Outstanding(Mil.): 14.43
Dividend: --
Yield (%): --

Financials

BRIEF-Diffusion Pharmaceuticals Files Prospectus Related To Offering Of Common Stock

* DIFFUSION PHARMACEUTICALS INC FILES PROSPECTUS RELATED TO OFFERING UP TO 12.3 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING‍​ Source text: (http://bit.ly/2nGHE9Q) Further company coverage:

06 Feb 2018

BRIEF-Diffusion Pharmaceuticals Announces $12 Mln Underwritten Public Offering

* DIFFUSION PHARMACEUTICALS ANNOUNCES $12 MILLION UNDERWRITTEN PUBLIC OFFERING

18 Jan 2018

BRIEF-Diffusion Pharmaceuticals Begins Phase 3 Clinical Trial With TSC In Glioblastoma Multiforme

* DIFFUSION PHARMACEUTICALS BEGINS PHASE 3 CLINICAL TRIAL WITH TSC IN GLIOBLASTOMA MULTIFORME

27 Dec 2017

BRIEF-Diffusion Pharma Files For Stock Offering For Up To About $15 Mln

* DIFFUSION PHARMACEUTICALS FILES FOR STOCK OFFERING FOR UP TO ABOUT $15 MILLION - SEC FILING Source text for Eikon: (http://bit.ly/2BbtOBi) Further company coverage:

21 Dec 2017

Earnings vs. Estimates